The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study

BACKGROUND: CDK4/6 inhibitors combined with endocrine therapy have significantly improved treatment outcomes for metastatic hormone receptor-positive (HR+) breast cancer patients. However, the impact of low HER2 expression on treatment response and progression-free survival (PFS) remains unclear. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Caliskan Yildirim, Eda, Atag, Elif, Coban, Ezgi, Umit Unal, Olcun, Celebi, Abdussamet, Keser, Murat, Uzun, Mehmet, Keskinkilic, Merve, Tanrikulu Simsek, Eda, Sari, Murat, Yavuzsen, Tugba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382953/
https://www.ncbi.nlm.nih.gov/pubmed/37343321
http://dx.doi.org/10.1016/j.breast.2023.06.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382953/
https://www.ncbi.nlm.nih.gov/pubmed/37343321
http://dx.doi.org/10.1016/j.breast.2023.06.006

Ejemplares similares